GBIM:OTCMKTS
GlobeImmune Inc
0,00010 US$
0,00%
(0,00) 1 d
29 sep., 15:48:52 GMT−4 · USD
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för GBIM …
Börsvärde
580,00
Genomsn. vol.
1,74 tn
Volym
0,00
52v högst
0,04 US$
52v lägst
0,00 US$
Utestående aktier
5,75 mn
Antal anställda
22
Börsvärde
580,00
Genomsn. vol.
1,74 tn
Volym
0,00
52v högst
0,04 US$
52v lägst
0,00 US$
Utestående aktier
5,75 mn
Antal anställda
22
Nyheter och artiklar
Från webbkällor och nyhetspartner
Vietnam.vn
·
för 1 dag sedan
Snabbläsning 16-10: Dow Jones stiger över 550 poäng då obligationsräntorna faller, PV Power uppskattar 9-månaders vinst till över 5 400 miljarder VND
HurBra.se
·
för 1 dag sedan
USA-börsen 15 oktober 2026: Vård lyfte, AI pressades
Simply Wall Street
·
för 4 minuter sedan
Did EU Backing Just Shift Ionis Pharmaceuticals (IONS) Investment Narrative?
MarketBeat
·
för 1 timme sedan
Red Rock Resorts, Inc. (NASDAQ:RRR) Stock Has Consensus Target Price of $71.94
Profil
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Om GlobeImmune Inc
Vd-
Anställda22
Grundades1 jan. 1995
HuvudkontorLouisville, Colorado, USA
Sektor-
Webbplatsglobeimmune.com